Modulation of lymphocyte trafficking and function

 

Immunosuppressive Gamma Delta T-Cells

We are developing first-in-class monoclonal antibodies targeting immunosuppressive gamma delta T-cells, galectin-9 and related mechanisms of immunosuppression in pancreatic, colorectal cancer and other solid tumors. Our therapeutics are aimed at oncology indications that have dismal prognosis and are currently suboptimally treated with available standard of care agents and immunotherapies.

We are conducting safety and efficacy validation of our lead therapeutic candidates in preparation for the first clinical trial.


  • Patient Need & Market Potential
    • Globally, approximately 400,000 people are diagnosed with pancreatic cancer each year, with more than 90 percent diagnosed at an advanced/metastatic stage
    • With a five-year survival rate at less than seven percent, pancreatic cancer is the third leading cause of cancer death
    • Colorectal cancer (CRC) is among the largest cancer burdens in the world today with approximately 700,000 people being diagnosed globally each year. Median survival of patients with unresectable metastatic CRC remains less than three years. Death from CRC is expected to nearly double within the next 20 years. Current immunotherapies are only efficacious in a small proportion of CRC patients (less than 15 percent) whose tumors demonstrate mismatch repair deficiency. Hence novel, more broadly effective therapeutic strategies to engage the patients' immune system are needed
    • Currently approved immunotherapies have been generally unsuccessful in this disease setting due to a highly immunosuppressive environment that wards off the body’s natural defenses
    • Our gamma delta T-cell/galectin-9 program aims to address this great unmet need in malignancies, particularly those with dismal prognoses that derive little benefit from current standards of care
  • Our Approach to Solving the Problem
    • Pre-clinical models validating our therapeutic concept show survival extensions in gold-standard animal models of pancreatic cancer that are superior to those previously observed in literature using approved treatments
    • Our approach is differentiated from traditional checkpoint inhibitors in immuno-oncology, and it has potential synergies with existing immunotherapies and current standards of care
    • It may also have broader applicability in the immuno-oncology space, with research underway expanding this initial work in pancreatic cancer and other solid tumors, including colorectal cancer
  • Collaborations
    • Our gamma delta T-cells/galectin-9 technology is exclusively licensed from the NYU School of Medicine and is based on the work of Dr. George Miller, Director of S. Arthur Localio Laboratories and Director of the Cancer Immunology Program at NYU School of Medicine. Part of the body of data supporting this approach was published in Nature Medicine and builds upon Dr. Miller’s work previously published in Cell.

We are conducting safety and efficacy validation of our lead therapeutic candidates in preparation for the first clinical trial.


Key data: PoC animal models of PDA, PoC in human cancers, developed lead therapeutic mAb clones to ∂1 Chain and Galectin-9

Human proof of concept pre-clinical data